SCHEMBL29567319

SCHEMBL29567319

CC(C)c1ccccc1-c1cc(OCCCC#N)nc(NS(=O)(=O)c2cnn(C)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 11/20 0.43
▸ HTR7 P34969 11/20 0.43
▸ DRD2 P14416 4/20 0.43
▸ HTR6 P50406 1/20 0.43
▸ HTR2A P28223 3/20 0.37
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ TYK2 P29597 1/20 0.35
▸ STAT3 P40763 1/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ LTB4R Q15722 1/20 0.33
▸ TSHR P16473 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CYBB P04839 1/20 0.32
▸ USP1 O94782 1/20 0.32
▸ TRPC5 Q9UL62 1/20 0.31
▸ EGFR P00533 2/20 0.31
▸ FGFR1 P11362 2/20 0.31
▸ KDR P35968 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310670 1.00 HTR1A (0.43) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL26808420 0.90 HTR1A (0.44) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL26808397 0.90 HTR1A (0.44) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL26808400 0.89 HTR1A (0.44) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL26808408 0.89 HTR1A (0.45) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL26808412 0.86 HTR1A (0.42) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL26808386 0.86 HTR1A (0.42) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL26808415 0.86 SMN1; SMN2 (0.45) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL29567073 0.84 HTR1A (0.43) HTR1AHTR7DRD2HTR6HTR2A
SCHEMBL24309659 0.84 HTR1A (0.43) HTR1AHTR7DRD2HTR6HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback